Phase 2 Schizophrenia Trial, Recruiting NCT05052853 Sponsor: China Medical University Hospital Condition: Schizophrenia
Back to Schizophrenia

Phase 2 Schizophrenia Trial, Recruiting

NCT05052853
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who show signs of a "prodromal" (early warning) phase of psychosis, meaning they experience at least one of the following: mild or partial psychotic symptoms (such as unusual thoughts or perceptions), brief episodes of psychotic symptoms that go away on their own, or a family history of psychosis combined with a noticeable decline in functioning.
  • People who still have significant symptoms — scoring at least 20 points on a standard symptom rating scale — after completing a 6-week health-promotion program at the start of the study.
  • People who are either currently taking antipsychotic medication (and have been on a stable, unchanged dose for at least 4 weeks before the study begins), or people who have not taken antipsychotic medication for at least 12 weeks (and would not take it during the study period).
  • People who are willing to take part and sign a written consent form after being fully informed about the study. For participants under 20 years old, a parent or guardian must also provide written consent.

Who may not be able to join:

  • People who have a diagnosed condition including intellectual disability, alcohol or substance use disorder, schizophrenia, schizoaffective disorder, delusional disorder, schizophreniform disorder, or psychosis caused by a substance, medication, or another medical condition (as defined by the DSM-5 diagnostic system).
  • People with a history of epilepsy, significant head injury, stroke, or other serious medical or neurological conditions that could affect the study results.
  • People whose routine blood or laboratory test results show clinically significant abnormalities (confirm with trial site).
  • People who are pregnant or breastfeeding.
  • People who would be unable to follow the study procedures as required.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 886 4 22052121

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
China Medical University Hospital
Registry
ClinicalTrials.gov
Start date
1 November 2021
Est. completion
1 October 2026

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Change from baseline in Scale of Prodromal Symptoms [SOPS] total score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov